Laurence Klotz1, Abdenour Nabid2, Celestia Higano3, Chris Ryanm4, Marlene Kebabdjian1, Joseph Chin5. 1. Division of Urology, Sunnybrook Health Sciences Centre, Toronto, ON; 2. Department of Radiation Oncology, Centre Hospitalier de Universitaire de Sherbrooke, Sherbrooke, QC; 3. Departments of Medicine and Urology, University of Washington Seattle Cancer Care Alliance, Seattle, WA; 4. Department of Medicine, Oregon Health Sciences University, Portland, OR; 5. Division of Urology, London Health Sciences Centre, London, ON.
Abstract
INTRODUCTON: We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy. METHODS: We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. Patients were randomized to dutasteride (0.5 mg/day) or placebo. All patients received androgen deprivation therapy (ADT), which was stopped at month 9 if the PSA level was <1.0 ng/mL. ADT was resumed when PSA increased to ≥5.0 ng/mL. End points included time off treatment, PSA nadir after 9 months of ADT, serum testosterone and dihydrotestosterone levels, and time to castrate-resistant prostate cancer (rising PSA while testosterone levels remain <50 ng/mL). RESULTS: There were 87 evaluable patients: 49 dutasteride, 38 placebo. In total, 80 patients completed one treatment cycle: 45 dutasteride, 35 placebo. The median time off treatment for patients reaching ≥5 ng/mL was 18.6 and 16.7 months for dutasteride and placebo, respectively (p = 0.7600). The median PSA nadir at 9 months was 0.1 and 0.075 ng/mL, respectively (p = 0.4486). There were no cases of androgen-independent prostate cancer. Our study limitations include its short duration with only one treatment cycle evaluated. CONCLUSIONS: This small-scale Phase II randomized controlled trial showed no benefit to the addition of dutasteride to an IAD regimen.
INTRODUCTON: We studied the effect of dutasteride on the length of the off-treatment period in prostate cancer patients on intermittent androgen deprivation (IAD) therapy. METHODS: We conducted a randomized, placebo-controlled Phase II trial in men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. Patients were randomized to dutasteride (0.5 mg/day) or placebo. All patients received androgen deprivation therapy (ADT), which was stopped at month 9 if the PSA level was <1.0 ng/mL. ADT was resumed when PSA increased to ≥5.0 ng/mL. End points included time off treatment, PSA nadir after 9 months of ADT, serum testosterone and dihydrotestosterone levels, and time to castrate-resistant prostate cancer (rising PSA while testosterone levels remain <50 ng/mL). RESULTS: There were 87 evaluable patients: 49 dutasteride, 38 placebo. In total, 80 patients completed one treatment cycle: 45 dutasteride, 35 placebo. The median time off treatment for patients reaching ≥5 ng/mL was 18.6 and 16.7 months for dutasteride and placebo, respectively (p = 0.7600). The median PSA nadir at 9 months was 0.1 and 0.075 ng/mL, respectively (p = 0.4486). There were no cases of androgen-independent prostate cancer. Our study limitations include its short duration with only one treatment cycle evaluated. CONCLUSIONS: This small-scale Phase II randomized controlled trial showed no benefit to the addition of dutasteride to an IAD regimen.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Marc R Theoret; Yang-Min Ning; Jenny J Zhang; Robert Justice; Patricia Keegan; Richard Pazdur Journal: N Engl J Med Date: 2011-06-15 Impact factor: 91.245
Authors: Leonard S Marks; Gerald L Andriole; John M Fitzpatrick; Claude C Schulman; Claus G Roehrborn Journal: J Urol Date: 2006-09 Impact factor: 7.450
Authors: Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson Journal: N Engl J Med Date: 2013-04-04 Impact factor: 91.245
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Howard L Parnes; Lori M Minasian; Paul A Godley; M Scott Lucia; Leslie G Ford Journal: N Engl J Med Date: 2013-08-15 Impact factor: 91.245
Authors: Francesco Giganti; Caroline M Moore; Nicola L Robertson; Neil McCartan; Charles Jameson; Simon R J Bott; Mathias Winkler; Giulio Gambarota; Brandon Whitcher; Ramiro Castro; Mark Emberton; Clare Allen; Alex Kirkham Journal: Eur Radiol Date: 2017-05-18 Impact factor: 5.315